Synergene Therapeutics Inc.

Annapolis, MD

UEI
W8E3G5851JK4
CAGE
43DC1
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

FY2025 rankings
Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1216 River Bay Rd, Annapolis, MD 21409, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $706,655
FY2024 $1,623,689
FY2023 $1,335,092

Contract awards

Award Agency Obligated Awarded
Application of a nanocomplex technology to the active permeation of the blood brain barrier (BBB) HDTRA120C0045 Defense Threat Reduction Agency $7,589,344
R & D- medical: biomedical (basic research) HHSN261201400038C National Cancer Institute (NIH) $222,900
Targeted nanocomplexed iron oxide for early detection with hyperthermia treatment of cancer HHSN261200900076C National Cancer Institute (NIH) $199,735
Sbir proposal for PHS 2009-1 topic 266 for a targeted nanocomplix for early detection of lung cancer HHSN261200900046C National Cancer Institute (NIH) $1,196,639

Grant awards

Award Agency Obligated Awarded
In delivered nanomedicine crossing the BBB continuously makes highly active bche. HDTRA11310049 Defense Threat Reduction Agency $5,083,968

Grant subawards

Prime recipient Prime award Amount Awarded
Children's Research Institute s SGT-53, a novel nanomedicine that crosses the BBB, augments immunotherapeutic response in pediatric brain cancers HT94252310987 $295,104

Quick answers

Is Synergene Therapeutics Inc. registered in SAM.gov?

Yes. Synergene Therapeutics Inc.'s SAM.gov registration is active through June 26, 2027.

What is Synergene Therapeutics Inc.'s CAGE code?

Synergene Therapeutics Inc.'s CAGE code is 43DC1, and its Unique Entity ID (UEI) is W8E3G5851JK4.

How much has Synergene Therapeutics Inc. received in federal contracts?

Federal contracts obligated $706,655 to Synergene Therapeutics Inc. in fiscal year 2025 and $3,665,435 in fiscal years 2023 through 2027.

How does Synergene Therapeutics Inc. rank among federal contractors?

Synergene Therapeutics Inc. ranked #20 in PSC AD92 and #59 in PSC AD in FY2025.

What is Synergene Therapeutics Inc.'s most recent federal award?

Synergene Therapeutics Inc.'s most recent federal contract award is Application of a nanocomplex technology to the active permeation of the blood brain barrier (BBB) (HDTRA120C0045), from Defense Threat Reduction Agency, on July 7, 2020.

On GovTribe

See Synergene Therapeutics Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe